| Original language | English (US) |
|---|---|
| Pages (from-to) | 607-609 |
| Number of pages | 3 |
| Journal | JAMA - Journal of the American Medical Association |
| Volume | 321 |
| Issue number | 6 |
| DOIs | |
| State | Published - Feb 12 2019 |
ASJC Scopus subject areas
- Medicine(all)
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018. / Hartung, Daniel M.; Johnston, Kirbee; Geddes, Jonah et al.
In: JAMA - Journal of the American Medical Association, Vol. 321, No. 6, 12.02.2019, p. 607-609.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018
AU - Hartung, Daniel M.
AU - Johnston, Kirbee
AU - Geddes, Jonah
AU - Leichtling, Gillian
AU - Priest, Kelsey C.
AU - Korthuis, P. Todd
N1 - Funding Information: Funding/Support: Dr Hartung is supported by grant R18HS024227 from the Agency for Healthcare Research and Quality, grants 1R01DA044284, R01DA046468, and 1R01DA045745 from the National Institute on Drug Abuse, and grant R01CE003008 from the US Centers for Disease Control and Prevention. Ms Priest is supported by grant F30DA044700 from the National Institute on Drug Abuse. Dr Korthuis is supported by grant U278601CE00 from the US Centers for Disease Control and Prevention and grants UG1DA015815 and UG3DA044831 from the National Institute on Drug Abuse. Funding Information: Conflict of Interest Disclosures: Dr Hartung reported receiving grants from AbbVie, the National Multiple Sclerosis Society, the National Institute on Drug Abuse, the National Center for Injury Prevention and Control at the Centers for Disease Control and Prevention, and the Patient-Centered Outcomes Research Institute (PCORI); being an associate editor for PCORI peer review; and serving on the advisory council for MedSavvy Scientific. Ms Johnston reported receiving grants from the National Multiple Sclerosis Society. Dr Korthuis reported serving as a principal investigator on trials funded by the National Institute on Drug Abuse that accept donated study medications from Indivior (buprenorphine/naloxone) and Alkermes (extended-release naltrexone). No other disclosures were reported.
PY - 2019/2/12
Y1 - 2019/2/12
UR - http://www.scopus.com/inward/record.url?scp=85061342630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061342630&partnerID=8YFLogxK
U2 - 10.1001/jama.2018.20391
DO - 10.1001/jama.2018.20391
M3 - Letter
C2 - 30747957
AN - SCOPUS:85061342630
SN - 0002-9955
VL - 321
SP - 607
EP - 609
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 6
ER -